Mark A. Meltz

Insider Reports History

Location
San Francisco, CA
Signature
/s/ Charles Newton, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Mark A. Meltz:

Company Role Class Num Shares Value Price $ Report Date Ownership
Kinnate Biopharma Inc. COO GENERAL COUNSEL SECRETARY Common Stock 0 $0 $2.59 03 Apr 2024 Direct
Lyell Immunopharma, Inc. General Counsel Option (right to buy) 100,000 09 Jun 2025 Direct
Kinnate Biopharma Inc. COO GENERAL COUNSEL SECRETARY Stock Option (right to buy) 0 03 Apr 2024 Direct

Insider Reports Filed by Mark A. Meltz

Symbol Company Period Transactions Value $ Form Type Role Filing Time
LYEL Lyell Immunopharma, Inc. 09 Jun 2025 1 $0 4 General Counsel 11 Jun 2025, 17:47
LYEL Lyell Immunopharma, Inc. 09 Jun 2025 0 $0 3 General Counsel 11 Jun 2025, 17:40
KNTE Kinnate Biopharma Inc. 03 Apr 2024 6 $0 4 COO GENERAL COUNSEL SECRETARY 05 Apr 2024, 16:55
KNTE Kinnate Biopharma Inc. 01 Mar 2024 1 -$1,445 4 COO GENERAL COUNSEL SECRETARY 05 Mar 2024, 17:00
KNTE Kinnate Biopharma Inc. 01 Dec 2023 1 -$1,217 4 COO General Counsel Secretary 05 Dec 2023, 17:00
KNTE Kinnate Biopharma Inc. 01 Sep 2023 1 -$1,271 4 COO General Counsel Secretary 06 Sep 2023, 18:00
KNTE Kinnate Biopharma Inc. 01 Jun 2023 1 -$2,326 4 COO General Counsel Secretary 05 Jun 2023, 17:00
KNTE Kinnate Biopharma Inc. 01 Mar 2023 1 -$3,324 4 COO General Counsel Secretary 03 Mar 2023, 16:57
KNTE Kinnate Biopharma Inc. 10 Feb 2023 1 $0 4 COO General Counsel Secretary 14 Feb 2023, 16:00
KNTE Kinnate Biopharma Inc. 01 Dec 2022 1 -$4,193 4 COO General Counsel Secretary 02 Dec 2022, 19:00
KNTE Kinnate Biopharma Inc. 01 Sep 2022 1 $0 4 COO General Counsel Secretary 02 Sep 2022, 17:00
KNTE Kinnate Biopharma Inc. 11 Feb 2022 1 $0 4 COO General Counsel Treasurer 15 Feb 2022, 15:01